This might explain why most progress has been made so far in the clinical development of antibody toxins that target cell surface molecules such as CD22 and CD25 expressed on certain malignancies of hematologic origin [34,35], where tumor cells are usually more accessible. Here, CD22 is linked to neoplasm.